Filter by Year:
Press Releases
-
Nov 12, 2024
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
-
Nov 04, 2024
Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update
-
Oct 10, 2024
Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors
-
Oct 01, 2024
Foghorn Therapeutics to Participate in the BMO Oncology Summit
-
Sep 03, 2024
Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer
-
Aug 28, 2024
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September
-
Aug 08, 2024
Foghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate Update
-
May 28, 2024
Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June
-
May 22, 2024
Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline
-
May 20, 2024
Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants
Displaying 1 - 10 of 91